BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 33152814)

  • 21. Mismatch repair deficiency is associated with MSI phenotype, increased tumor-infiltrating lymphocytes and PD-L1 expression in immune cells in ovarian cancer.
    Xiao X; Dong D; He W; Song L; Wang Q; Yue J; Xie L
    Gynecol Oncol; 2018 Apr; 149(1):146-154. PubMed ID: 29496294
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characterization of immune regulatory molecules B7-H4 and PD-L1 in low and high grade endometrial tumors.
    Bregar A; Deshpande A; Grange C; Zi T; Stall J; Hirsch H; Reeves J; Sathyanarayanan S; Growdon WB; Rueda BR
    Gynecol Oncol; 2017 Jun; 145(3):446-452. PubMed ID: 28347512
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Heterogenous loss of mismatch repair (MMR) protein expression: a challenge for immunohistochemical interpretation and microsatellite instability (MSI) evaluation.
    McCarthy AJ; Capo-Chichi JM; Spence T; Grenier S; Stockley T; Kamel-Reid S; Serra S; Sabatini P; Chetty R
    J Pathol Clin Res; 2019 Apr; 5(2):115-129. PubMed ID: 30387329
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Microsatellite instability and mismatch repair protein expressions in lymphocyte-predominant breast cancer.
    Horimoto Y; Thinzar Hlaing M; Saeki H; Kitano S; Nakai K; Sasaki R; Kurisaki-Arakawa A; Arakawa A; Otsuji N; Matsuoka S; Tokuda E; Arai M; Saito M
    Cancer Sci; 2020 Jul; 111(7):2647-2654. PubMed ID: 32449246
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical significance of programmed cell death-ligand 1 expression and the immune microenvironment at the invasive front of colorectal cancers with high microsatellite instability.
    Korehisa S; Oki E; Iimori M; Nakaji Y; Shimokawa M; Saeki H; Okano S; Oda Y; Maehara Y
    Int J Cancer; 2018 Feb; 142(4):822-832. PubMed ID: 29044503
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Relationship between PD-L1 protein expression and gene amplification in gastric cancer tissues].
    Liu Y; Wang JF; Li XW; Bu P; Bai W; Li LM
    Zhonghua Bing Li Xue Za Zhi; 2018 Aug; 47(8):597-602. PubMed ID: 30107664
    [No Abstract]   [Full Text] [Related]  

  • 27. New insights into the inflamed tumor immune microenvironment of gastric cancer with lymphoid stroma: from morphology and digital analysis to gene expression.
    Gullo I; Oliveira P; Athelogou M; Gonçalves G; Pinto ML; Carvalho J; Valente A; Pinheiro H; Andrade S; Almeida GM; Huss R; Das K; Tan P; Machado JC; Oliveira C; Carneiro F
    Gastric Cancer; 2019 Jan; 22(1):77-90. PubMed ID: 29779068
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Significance of druggable targets (PD-L1, KRAS, BRAF, PIK3CA, MSI, and HPV) on curatively resected esophageal squamous cell carcinoma.
    Lee HK; Kwon MJ; Ra YJ; Lee HS; Kim HS; Nam ES; Cho SJ; Park HR; Min SK; Seo J; Choe JY; Min KW; Kang SY
    Diagn Pathol; 2020 Oct; 15(1):126. PubMed ID: 33054840
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Transcriptomic Landscape of Gastric Cancer: Insights into Epstein-Barr Virus Infected and Microsatellite Unstable Tumors.
    Gullo I; Carvalho J; Martins D; Lemos D; Monteiro AR; Ferreira M; Das K; Tan P; Oliveira C; Carneiro F; Oliveira P
    Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 30018250
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Microsatellite instability (MSI-H) is associated with a high immunoscore but not with PD-L1 expression or increased survival in patients (pts.) with metastatic colorectal cancer (mCRC) treated with oxaliplatin (ox) and fluoropyrimidine (FP) with and without bevacizumab (bev): a pooled analysis of the AIO KRK 0207 and RO91 trials.
    Noepel-Duennebacke S; Juette H; Schulmann K; Graeven U; Porschen R; Stoehlmacher J; Hegewisch-Becker S; Raulf A; Arnold D; Reinacher-Schick A; Tannapfel A
    J Cancer Res Clin Oncol; 2021 Oct; 147(10):3063-3072. PubMed ID: 33675399
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The PD-1, PD-L1 expression and CD3+ T cell infiltration in relation to outcome in advanced gastric signet-ring cell carcinoma, representing a potential biomarker for immunotherapy.
    Jin S; Xu B; Yu L; Fu Y; Wu H; Fan X; Wei J; Liu B
    Oncotarget; 2017 Jun; 8(24):38850-38862. PubMed ID: 28418918
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Programmed death-ligand 1 expression in gastric cancer: correlation with mismatch repair deficiency and HER2-negative status.
    Wang L; Zhang Q; Ni S; Tan C; Cai X; Huang D; Sheng W
    Cancer Med; 2018 Jun; 7(6):2612-2620. PubMed ID: 29673110
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expression of DNA Mismatch Repair Proteins, PD1 and PDL1 in Barrett's Neoplasia.
    Saller JJ; Mora LB; Nasir A; Mayer Z; Shahid M; Coppola D
    Cancer Genomics Proteomics; 2022; 19(2):145-150. PubMed ID: 35181584
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High density of cytotoxic T-lymphocytes is linked to tumoral PD-L1 expression regardless of the mismatch repair status in colorectal cancer.
    Möller K; Blessin NC; Höflmayer D; Büscheck F; Luebke AM; Kluth M; Hube-Magg C; Zalewski K; Hinsch A; Neipp M; Mofid H; Lárusson H; Daniels T; Isbert C; Coerper S; Ditterich D; Rupprecht H; Goetz A; Bernreuther C; Sauter G; Uhlig R; Wilczak W; Simon R; Steurer S; Minner S; Burandt E; Krech T; Perez D; Izbicki JR; Clauditz TS; Marx AH
    Acta Oncol; 2021 Sep; 60(9):1210-1217. PubMed ID: 34092167
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinicopathological features of 22C3 PD-L1 expression with mismatch repair, Epstein-Barr virus status, and cancer genome alterations in metastatic gastric cancer.
    Kawazoe A; Shitara K; Kuboki Y; Bando H; Kojima T; Yoshino T; Ohtsu A; Ochiai A; Togashi Y; Nishikawa H; Doi T; Kuwata T
    Gastric Cancer; 2019 Jan; 22(1):69-76. PubMed ID: 29859006
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Triple-Negative Breast Cancer: Intact Mismatch Repair and Partial Co-Expression of PD-L1 and LAG-3.
    Wu S; Shi X; Wang J; Wang X; Liu Y; Luo Y; Mao F; Zeng X
    Front Immunol; 2021; 12():561793. PubMed ID: 33717059
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comprehensive analysis of potential immunotherapy genomic biomarkers in 1000 Chinese patients with cancer.
    Zang YS; Dai C; Xu X; Cai X; Wang G; Wei J; Wu A; Sun W; Jiao S; Xu Q
    Cancer Med; 2019 Aug; 8(10):4699-4708. PubMed ID: 31270941
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Is Adjuvant Chemotherapy Necessary for Patients with Deficient Mismatch Repair Gastric Cancer?-Autophagy Inhibition Matches the Mismatched.
    Tsai CY; Lin TA; Huang SC; Hsu JT; Yeh CN; Chen TC; Chiu CT; Chen JS; Yeh TS
    Oncologist; 2020 Jul; 25(7):e1021-e1030. PubMed ID: 32058649
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Programmed Death-Ligand 1 Expression, Microsatellite Instability, Epstein-Barr Virus, and Human Papillomavirus in Nasopharyngeal Carcinomas of Patients from the Philippines.
    Chang AMV; Chiosea SI; Altman A; Pagdanganan HA; Ma C
    Head Neck Pathol; 2017 Jun; 11(2):203-211. PubMed ID: 27807760
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PD-L1 is a double-edged sword in colorectal cancer: the prognostic value of PD-L1 depends on the cell type expressing PD-L1.
    Ho HL; Chou TY; Yang SH; Jiang JK; Chen WS; Chao Y; Teng HW
    J Cancer Res Clin Oncol; 2019 Jul; 145(7):1785-1794. PubMed ID: 31129768
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.